Literature DB >> 1358790

Evidence implicating heterozygous deletion of chromosome 7 in the pathogenesis of familial leukemia associated with monosomy 7.

K M Shannon1, A G Turhan, P C Rogers, Y W Kan.   

Abstract

Complete or partial monosomy 7 is a recurring cytogenetic abnormality in acute myelogenous leukemia (AML) and myeloproliferative syndromes (MPS) and is particularly common in patients with Fanconi's anemia and in secondary AML. A familial form of monosomy 7 has been recognized in which two or more siblings develop MPS or AML before age 20. We tested the hypothesis that a recessive cancer susceptibility locus on chromosome 7 was important in the pathogenesis of leukemia in familial monosomy 7 by determining the parental origins of the chromosome 7 retained in the bone marrows of three pairs of affected siblings. We found no overlapping region where all three pairs retained DNA derived from the same paternal or maternal chromosome. These data suggest that inactivation of a single allele of a putative tumor-suppressor gene may be sufficient to contribute to leukemic transformation in familial monosomy 7.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358790     DOI: 10.1016/s0888-7543(05)80293-9

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  4 in total

1.  The rate of telomere sequence loss in human leukocytes varies with age.

Authors:  R W Frenck; E H Blackburn; K M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

Review 2.  Familial myelodysplastic syndromes: a review of the literature.

Authors:  Elena Liew; Carolyn Owen
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

3.  Genetic predispositions to childhood leukemia.

Authors:  Elliot Stieglitz; Mignon L Loh
Journal:  Ther Adv Hematol       Date:  2013-08

4.  Biomarkers of leukemia risk: benzene as a model.

Authors:  M T Smith; L Zhang
Journal:  Environ Health Perspect       Date:  1998-08       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.